ABSTRACT
Background: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Various drug treatment protocols using drugs such as Vitamin C, hydroxychloroquine, Remdesivir, Tocilizumab, Favipiravir, Interferons, etc. were recommended by governments across globe. Aim and Objectives: The present study aims to assess Drug Prescribing Pattern and Clinical Outcome in Intensive Care Unit (ICU) of a Dedicated COVID Hospital. Materials and Methods: The present study was of retrospective, analytical type conducted at Government Medical College, Jalgaon which was a Dedicated COVID hospital. Medical records of 111 patients of Covid 19 who received treatment in ICU of Government Medical College, Jalgaon from August 2020 to December 2020 were included in the present study. Results: Out of 111 patients with confirmed Covid19 infection, majority belonged to the age group of 51–60 years (24.3%), followed by 41–50 years (22.5%) and 61–70 years (20.7%). On analyzing the primary drugs prescribed, heparin was most commonly prescribed drug (95.5%) followed by corticosteroid (94.6%), Tocilizumab (39%), Oseltamivir (37%), and Remdesivir (31%). Out of patients who were cured, the majority had received heparin followed by corticosteroid, Oseltamivir, Remdesivir, Oseltamivir, and Tocilizumab. Conclusion: In the present study corticosteroid and heparin were the most commonly prescribed drugs. Clinical outcomes were better in patient who received remdesivir, steroid, and heparin. The present study is an attempt to fill the lacuna of dearth of data on prescribing pattern of various drugs used in the treatment of moderate to severe Covid19 disease.
ABSTRACT
Background: The severe acute respiratory syndrome coronavirus 2 (COVID 19) is a global pandemic since December 2019. The subject expert committee of the Central Drugs Standard Control Organization made recommendations for Restricted Emergency Approval of COVID-19 virus vaccine of M/s Serum Institute of India ChAdOx1 nCoV-19 vaccine (AZD1222) COVISHIELD™ which was developed at Oxford University. In India, this vaccine was launched on January 16, 2021, and healthcare workers were included first in this vaccination program. Aim and Objectives: This study aimed to record and analyzes all the adverse events following the immunization (AEFI) in healthcare workers for monitoring the safety and find the correlation if any. Materials and Methods: This was a prospective observational study. After obtaining Institutional Ethics committee approval, we collected the data by phone call to the participants within 3 days after the first and second dose of the vaccine. We collected the data from 100 healthcare workers randomly with their consent. Results: The most common adverse effect found was myalgia followed by local pain at the injection site after the first dose. About 92% of participants did not react to the second dose of the vaccine. Conclusion: There were no serious adverse events after the first as well as the second dose of vaccination. More studies and monitoring are needed to find out any unexpected reactions following COVID-19 vaccination.